- Research article
- Open Access
- Open Peer Review
Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
BMC Medical Genetics volume 9, Article number: 105 (2008)
The specific skipping of an exon, induced by antisense oligonucleotides (AON) during splicing, has shown to be a promising therapeutic approach for Duchenne muscular dystrophy (DMD) patients. As different mutations require skipping of different exons, this approach is mutation dependent. The skipping of an entire stretch of exons (e.g. exons 45 to 55) has recently been suggested as an approach applicable to larger groups of patients. However, this multiexon skipping approach is technically challenging. The levels of intended multiexon skips are typically low and highly variable, and may be dependent on the order of intron removal. We hypothesized that the splicing order might favor the induction of multiexon 45–55 skipping.
We here tested the feasibility of inducing multiexon 45–55 in control and patient muscle cell cultures using various AON cocktails.
In all experiments, the exon 45–55 skip frequencies were minimal and comparable to those observed in untreated cells.
We conclude that current state of the art does not sufficiently support clinical development of multiexon skipping for DMD.
Antisense-mediated exon skipping is emerging as a very promising therapeutic approach for Duchenne muscular dystrophy (DMD) . The aim of this approach is to restore the disrupted reading frame of DMD transcripts, and allow synthesis of partly functional, internally deleted Becker-like dystrophins, rather than prematurely truncated non-functional Duchenne dystrophins. This can be achieved by antisense oligonucleotides (AONs) that target specific exons and hide them from the splicing machinery during pre-mRNA splicing, resulting in the skipping of said exons . Proof of concept of this strategy has been obtained in numerous patient-derived cell cultures with different types of mutations, the mdx mouse model and recently in a first clinical trial where AONs were injected locally in the tibialis anterior muscle of 4 Duchenne patients [1, 3–9]. One of the disadvantages of this therapy is its mutation specificity: different exons have to be skipped to restore the reading frame for different mutations . Fortunately, most mutations involve deletions of one or more exons between exon 45 and 53 or between exon 2–20 (50% and 15% of all mutations, respectively) . Therefore, restoration of the reading frame for over 50% of all patients (75% of deletion patients) is theoretically feasible using a strategically selected set of only 10 exons . Skipping of exon 51 is beneficial for the largest group of patients (19% of all deletions, or 13% of all Duchenne patients, (Aartsma-Rus et al. accepted manuscript).
Nevertheless, it would be more straightforward if a single formulation of AONs would be applicable to an even larger group of patients. To achieve this, we and others suggested skipping of a stretch of consecutive exons simultaneously (multiexon skipping) [4, 13]. An added advantage of multiexon skipping is that it allows artificial induction of deletions known to be associated with mild phenotypes. We previously reported the feasibility of skipping a stretch of exons 45 through 51 (applicable to 13% of Duchenne patients) after targeting only the two outer exons with a mix of two AONs . Multiexon skipping levels could be increased by combining the two individual AONs in one molecule [4, 14]. Alternatively, a cocktail of AONs targeting all individual exons present in the stretch to be skipped can be employed. This has been successfully applied to induce exon 20–26 skipping in the mdx mouse model . However, using cocktails to induce the simultaneous skipping of an increasing number of exons is more challenging, due to the increasing occurrence of intermediate splicing products (personal observation and Steve Wilton, personal communication). These out-of-frame splice intermediates in fact dilute the levels of intended multiexon skipping.
We have repeatedly observed that the feasibility of skipping larger stretches of exons is also limited when using AONs targeting the outer exons: anticipated multiexon skipping patterns were not or not reproducibly induced. This is probably due to the fact that DMD introns are extremely large and DMD pre-mRNA is cotranscriptionally spliced . E.g. inducing exon 17–48 multiexon skipping is (nearly) impossible, as exon 17 is joined to exon 16 long before exon 48 is even transcribed (an estimated 4.5 h later) [2, 16]. However, as DMD intron sizes vary between 107 bp and 360 kb it is not inconceivable that some smaller downstream introns are spliced out prior to larger upstream exons. The most obvious examples would be intron 44, which is 240 kb. Subsequent introns are shorter, until intron 55, which is 120 kb. If the smaller introns (45 through 54) are indeed spliced out prior to intron 44 and intron 55, this would result in an "exon 45–55 block" (see Figure 1) . This hypothesis is underlined by our earlier finding of spontaneous exon 45–55 skipping in untreated control and patient myotube cultures, indicating that the acceptor splice sites of intron 44 and 55 can compete . The existence of an exon 45–55 block implies that exon 45–55 multiexon skipping may be more easily achieved than other and previously studied multiexon skips [12, 14]. Notably, exon 45–55 multiexon skipping would be beneficial for ~30% of Duchenne patients present in the Leiden DMD mutation database  and almost 65% of the French UMD database . In addition exon 45–55 deletions are associated with very mild Becker phenotypes and have even been found in asymptomatic individuals . In this report we therefore focus on the feasibility of enhancing exon 45–55 multiexon skipping in patient and control myotube cultures using different approaches. However, we were unable to increase the levels over those observed due to alternative splicing.
AONs used for this study (Table 1, 2, 3) were h45AON5L, h46AON26L, h47AON2, h47AON5 (exon 47 skipping requires double targeting), h48AON6, h49AON1, h50AON1, h51AON1, h52AON4, h53AON1, h54AON1 and h55AON5. All AONs have been described previously ([17, 18] (Heemskerk, accepted manuscript), except for h52AON4 (uuccaacuggggacgccucuguucc) and the linked AON, which consists of previously described AONs h45AON5L and h55AON5 linked by 10 uracil nucleotides. All AONs consist of 2'-O-methyl RNA and contain a full-length phosphorothioate backbone (Eurogentec, Belgium).
Myogenic cell cultures and AON transfections
Primary myoblasts from an anonymous human control and two anonymous Duchenne patients, with deletions of exon 48–50 and exon 46–50 respectively [3, 4] were cultured and differentiated into myotubes in 6 wells plates, as described . Cultures were transfected with mixtures of 200 nM of each AON, or 100 nM of each AON in the cocktail experiment, and 2.5 μl polyethyleneimine (PEI, Exgen 500, MBI Fermentas) per μg AON for three hours. Each combination was tested in six-plo and for each experiment six untreated wells were used as reference.
RNA isolation and RT-PCR analysis
RNA was isolated ~28 hours after transfection using RNA-Bee (Campro Scientific) as described elsewhere . RT-PCR analysis, sequence analysis and DNA lab chip analysis (Agilent Technologies) were performed as described [3, 4]. Primers used for RT-PCR analysis were designed in exons upstream and downstream of exon 45 and 55, respectively. Additional primers flanking exon 45 and exon 55 were used to confirm successful transfection of individual AONs (sequence on request).
Western blot analysis
Protein was isolated 48 hours after AON treatment as described elsewhere . Samples were boiled for 5 minutes, loaded on a 4–7% gradient polyacrylamide gel and run overnight at 4°C. Gels were blotted to nitrocellulose BA83 (Whatman, Schleicher & Schuell, Germany) for 6 hours at 4°C. Blots were blocked with 5% non-fat dried milk (Campina Melkunie, the Netherlands) in TBS followed by an overnight incubation with NCL-DYS1 (dilution 1:125, Novocastra, UK) in TBS plus 0.05% Tween20 to detect dystrophin. The fluorescent IRDye 800 CW goat-anti-mouse IgG (dilution 1:5000, Li-Cor, NE, USA) was used as a secondary antibody. Blots were visualized with the Odyssey system and software (Li-Cor, NE, USA).
Results and discussion
We hypothesized that multiexon 45–55 skipping might be induced or enhanced using different AONs and combination strategies (Figure 1). If the "exon block" hypothesis is correct, the exon 45 and exon 56 splice acceptor sites compete for the splice donor site of exon 44 (Figure 1B). Even though exon 45 is closer to exon 44 than exon 56 (248 kb vs 370 kb), exon 45 has a weaker acceptor site than exon 56 (0.76 vs 0.97, respectively). This might explain why exon 45–55 are occasionally alternatively or aberrantly spliced out. Targeting the two outer exons (exon 45 and exon 55) will increase the chance that exon 44 and exon 56 are joined (Figure 1C). To enhance the chance that both AONs hybridize to the same pre-mRNA transcript we included an AON where AONs targeting exon 45 and exon 55 are linked by 10 uracil nucleotides. Finally, we tested a cocktail of AONs targeting each individual exon from exon 45 to exon 55 (Figure 1D). This should result in exon 45–55 skipping regardless of the exon block hypothesis. However, this was also expected to generate many intermediate products due to the fact that in some transcripts not all exons will be targeted. Different AON chemistries are available . These include phosphorodiamidate morpholinos, which are very hard to transfect in vitro, and locked nucleic acids, which have a high propensity to bind to other locked nucleic acid oligomers, thus making an approach using a combination complicated . We thus used 2'-O-methyl phosphorothioate AONs, as these can be transfected at high efficiencies, and efficient AONs for the targeted exons were available.
Myotube cultures from a healthy individual and two Duchenne patients were treated with the different combinations of AONs (Table 1, 2, 3) and RNA was isolated on the subsequent day. Each combination was tested in at least six individual samples. As exon 45–55 skipping was previously observed in untreated samples  and its frequency varied between different cell batches (Table 1, 2, 3 and data not shown), for each experiment RNA was isolated from 6 untreated samples of the same cell batch as the treated cells. The frequencies of exon 45–55 skipping, as determined by RT-PCR analysis, were compared with and without treatment (Example shown in Figure 2, summary in Table 1, 2, 3). Putative exon 45–55 skipping products were verified by sequencing analysis (data not shown). Unfortunately, similar frequencies were observed, both in control and patient cell cultures, regardless of the combination of AONs used. Efficient transfection was confirmed by RT-PCR focusing on the individually targeted exons (data not shown). In addition to the occasional exon 45–55 skipping we observed several intermediate products, especially after treatment with the AON cocktail (Figure 2 middle panel, Table 1, 2, 3). Note that as the non skipped fragment is relatively large, it was not always amplified. Due to the lack of this reference value, assessment of exon 45–55 skipping levels was difficult. For a number of samples we determined the absolute amount of exon 45–55 skip product, or alternatively, the amount of exon 45–55 skip product relative to the amount of exon 44–45 product (which has a similar length as the skip product, but requires a different reverse PCR primer). In both cases, no differences were observed between multiexon skip levels before and after AON treatment. The exon 45–55 skipping observed after AON treatment is thus most likely due to naturally occurring alternative or aberrant splicing rather than through AON induction. This alternative splicing occurs at very low levels, as confirmed by Western blot analysis where no dystrophin was observed before or after AON treatment of the exon 48–50 deleted cells (Figure 3). Since levels of 1% of wild type dystrophin could be detected, this indicates that if this naturally occurring exon skipping does result in dystrophin production, levels are below 1%.
We conclude that, despite being theoretically a promising approach, the current state of the art does not sufficiently support clinical development of multiexon 45–55 skipping for DMD. In order to explore the frontiers of multiexon skipping, more information on the order and timing of DMD intron removal is required. Considering the urgent need for therapy, straightforward clinical development of single exon skipping, at this point being reproducible and efficient, should be preferred. In fact, single exon 51 skipping induced by 2'-O-methyl phosphorothioate AON PRO051 is currently in phase I/II clinical trials , clinical studies based on single exon 44 skipping trials are being prepared for, and other single exon skipping AONs will follow soon. Although single exon skipping may be applicable for relatively smaller groups of patients, skipping of exons 44, 45, 51 and 53 together would be beneficial to over 50% of all deletion patients, or over 35% of all patients in the Leiden DMD mutation database (Aartsma-Rus et al. accepted manuscript).
antisense oligonucleotides, DMD: Duchenne muscular dystrophy, UMD: Universal mutation database.
van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al: Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007, 357: 2677-2686. 10.1056/NEJMoa073108.
Aartsma-Rus A, van Ommen GJ: Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA. 2007, 13: 1609-1624. 10.1261/rna.653607.
Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, et al: Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet. 2003, 12: 907-14. 10.1093/hmg/ddg100.
Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, et al: Antisense-induced multiexon skipping for duchenne muscular dystrophy makes more sense. Am J Hum Genet. 2004, 74: 83-92. 10.1086/381039.
Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC: Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet. 2007, 8: 43-10.1186/1471-2350-8-43.
Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, et al: Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med. 2003, 8: 1009-1014. 10.1038/nm897.
Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, et al: Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA. 2005, 102: 198-203. 10.1073/pnas.0406700102.
Takeshima Y, Wada H, Yagi M, Ishikawa Y, Minami R, Nakamura H, et al: Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev. 2001, 23: 788-90. 10.1016/S0387-7604(01)00326-6.
van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, et al: Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001, 10: 1547-54. 10.1093/hmg/10.15.1547.
van Deutekom JC, van Ommen GJ: Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet. 2003, 4: 774-83. 10.1038/nrg1180.
Aartsma-Rus A, van Deutekom JC, Fokkema IF, van Ommen GJ, den Dunnen JT: Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve. 2006, 34: 135-144. 10.1002/mus.20586.
Aartsma-Rus A, van Deutekom JC: Antisense-Mediated Reading-Frame Restoration as a Genetic Therapy for Duchenne Muscular Dystrophy. Antisense Elements (Genetics) Research Focus. Edited by: Hernandes AG. 2007, Novapublishers
Beroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, et al: Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat. 2007, 28: 196-202. 10.1002/humu.20428.
Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC: Exploring the Frontiers of Therapeutic Exon Skipping for Duchenne Muscular Dystrophy by Double Targeting within One or Multiple Exons. Mol Ther. 2006, 14: 401-407. 10.1016/j.ymthe.2006.02.022.
Fall AM, Johnsen R, Honeyman K, Iversen P, Fletcher S, Wilton SD: Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther. 2006, 4: 3-10.1186/1479-0556-4-3.
Tennyson CN, Klamut HJ, Worton RG: The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced. Nat Genet. 1995, 9: 184-90. 10.1038/ng0295-184.
Aartsma-Rus A, Bremmer-Bout M, Janson A, Den Dunnen J, van Ommen G, van Deutekom J: Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord. 2002, 12: S71-S77. 10.1016/S0960-8966(02)00086-X.
Aartsma-Rus A, Winter CL, Janson AAM, Kaman WE, van Ommen GJ, den Dunnen JT, et al: Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides. 2005, 15: 284-297. 10.1089/oli.2005.15.284.
Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson A, Den Dunnen J, van Ommen GJ, et al: Comparative analysis of antisense oligonucleotide analogs for tageted DMD exon 46 skipping in muscle cells. Gene Therapy. 2004, 11: 1391-1398. 10.1038/sj.gt.3302313.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/9/105/prepub
The research in this study was financed by the Dutch Duchenne Parent Project (the Netherlands) and ZonMw (the Netherlands). The LUMC is part of the EU funded TREAT-NMD network of excellence.
The authors declare that they have no competing interests.
LvV and CdW performed experiments, JvD and G-JvO helped draft the manuscript and participated in the coordination and design of experiments, AAR performed experiments, conceived of the study, participated in the design and coordination and drafted the manuscript. All authors read and approved of the final manuscript.
About this article
Cite this article
van Vliet, L., de Winter, C.L., van Deutekom, J.C. et al. Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy. BMC Med Genet 9, 105 (2008) doi:10.1186/1471-2350-9-105
- Duchenne Muscular Dystrophy
- Duchenne Muscular Dystrophy
- Single Exon
- Promising Therapeutic Approach
- Uracil Nucleotide